Table 1.
Epidemiology and clinical characteristics of five COVID-19 cases.
Case 1 | Case 2 | Case 3 | Case 4 | Case 5 | |
---|---|---|---|---|---|
Gender (M/F) | F | M | M | M | M |
Age (y/m) | 10 m | 5.6 y | 8 m | 1.2 y | 2 m |
Exposure history | No | Grandmother confirmed | No | No | Parents and grandparents suspected |
First clinical manifestation | Paroxysmal crying, vomiting, currant jelly-like stool | Abdominal pain | Convulsion | Vomiting, diarrhea | Drowsiness and poor feeding, diarrhea |
Time from illness onset to fever | 30 h | 2 days | 6 h | 5 days | — |
Fever at presentation or prior to presentation | At presentation | No | At presentation | At presentation | No |
Highest temperature (°C) during the course | 39.8 | 39 | 38.5 | 37.9 | — |
Days from illness onset to admission | 1.25 | 2 | 0.25 | 6 | 3 |
Underlying or coexisting disease | Intussusception | Acute suppurative appendicitis perforation with localized peritonitis | Traumatic brain injury | Hydronephrosis and stone in the left kidney, rotavirus infection | No |
Complications | Shock; MODS (liver, kidney, myocardium, blood coagulation, intestinal); acute respiratory failure | No | No | Acute respiratory failure; acute heart failure; shock; MODS (liver, kidney, myocardium) | Myocardium function damaged |
Treatment | |||||
Antiviral therapy | Intravenous ribavirin, aerosol inhalation of interferon | Aerosol inhalation of interferon | Intravenous ribavirin, aerosol inhalation of interferon | Intravenous ribavirin, aerosol inhalation of interferon | Aerosol inhalation of interferon |
Methylprednisolone | 2 mg/(kg·d) × 5d | No | No | 2 mg/(kg·d) × 3d | No |
Intravenous immunoglobulin | 500 mg/(kg·d) × 3d | No | No | 500 mg/(kg·d) × 4d | No |
Oxygen inhalation | Nasal cannula | No | Nasal cannula | Nasal cannula | No |
Invasive mechanical ventilation | Yes | No | No | Yes | No |
Blood purification | PE+CRRT | No | No | PE+CRRT | No |
Length of stay (days) | 36 | 10 | 14 | 17 | 15 |
Outcomes | Died | Cured | Cured | Cured | Cured |